News
Sun Pharma Partner Philogen Resubmits EMA Marketing Application for Nidlegy
Under a licensing agreement signed with Philogen in May 2023, Sun Pharma holds exclusive commercialization rights for Nidlegy in Europe, Australia and New Zealand for the treatment of skin cancers.

